title: Preventive effects of batroxobin on experimental canine coronary thrombosis.
abstract: The thrombolytic effects of urokinase (UK) and preventive effects of batroxobin, heparin, and aspirin on the recurrence of thrombosis in the coronary artery were studied in 118 anesthetized dogs with severe endothelial denudation and luminal stenosis of the coronary artery. Occlusive thrombi developed in 68 (58%) preparations (dogs), accompanied by a decrease of coronary blood flow and pressure, an electrocardiographic ST elevation, and epicardial cyanosis. An intravenous infusion of 20,000 IU/kg of UK reopened the occluded coronary artery in all 32 preparations with 1-h-old thrombi, in 6 (86%) of 7 preparations with 2-h-old thrombi, and in 5 (83%) of 6 preparations with 3-h-old thrombi. However, recanalization was not observed in preparations with thrombi more than 4-h-old. Occlusion recurred within 6 h after recanalization in 2 (18%) of 18 preparations pretreated with batroxobin (1-2 BU/kg) (p less than .005 vs. control UK group), in 1 (14%) of 7 preparations administered a continuous infusion of 30 U/kg per h of heparin (p less than .05 vs. control UK group), in 4 (57%) of 7 preparations pretreated with 2 mg/kg of aspirin, and in 7 (64%) of 11 preparations not pretreated (control UK group). Complete prevention was observed only in the group administered 2 BU/kg of batroxobin. Histologically, these thrombi closely simulated clinical arterial thrombi. Myocardial hemorrhage and contraction band necrosis were observed in the reperfused hearts. In conclusion, experimental canine coronary thrombi more than 4-h-old were resistant to thrombolytic therapy, and batroxobin and heparin were effective in the prevention of coronary reocclusion.
authors.affiliation: Second Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Tomaru
authors.forename: Y
authors.initials: Y
authors.lastname: Uchida
authors.forename: H
authors.initials: H
authors.lastname: Sonoki
authors.forename: T
authors.initials: T
authors.lastname: Sugimoto
mesh_terms: D000818:Animals; D001241:Aspirin / Q000627:therapeutic use; D012103:Batroxobin / Q000627:therapeutic use*; D003327:Coronary Disease / Q000517:prevention & control*; D003328:Coronary Thrombosis / Q000473:pathology / Q000517:prevention & control*; D004195:Disease Models, Animal; D004285:Dogs; D004562:Electrocardiography; D005340:Fibrinogen / Q000378:metabolism; D006439:Hemodynamics; D006493:Heparin / Q000627:therapeutic use; D012008:Recurrence; D012697:Serine Endopeptidases / Q000627:therapeutic use*; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use
chemical_list: D005340:Fibrinogen; D006493:Heparin; D012103:Batroxobin; D012697:Serine Endopeptidases; D014568:Urokinase-Type Plasminogen Activator; D001241:Aspirin